{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:28:31Z","timestamp":1773674911849,"version":"3.50.1"},"reference-count":83,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T00:00:00Z","timestamp":1316476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Natural killer T cells are T lymphocytes with unique activation and effector properties. The majority of NKT cells, termed type-I or iNKT cells, recognize lipid antigens presented on MHC-like CD1d molecules. Type-I NKT cells have the capacity to rapidly secrete various cytokines upon activation, thereby regulate immune responses exerts dominant anti-tumor and anti-microbial effector functions. Specific activation of type-I NKT cells in mouse models boosts immunity and prevents metastasis, which has led to a number of phase I-II clinical trials. Since the discovery of NKT cells other subsets with different specificities and effector functions have been described. This article briefly reviews the physiological functions of NKT cell subsets, their implications in cancer and the attempts that have been made to employ NKT cells for immune therapy of cancer.<\/jats:p>","DOI":"10.3390\/cancers3033661","type":"journal-article","created":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T11:42:06Z","timestamp":1316518926000},"page":"3661-3675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy"],"prefix":"10.3390","volume":"3","author":[{"given":"Michael","family":"Nowak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Bonn, Sigmund-Freud-Strasse 25, Bonn 53127, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G.H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Bonn, Sigmund-Freud-Strasse 25, Bonn 53127, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2011,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.15.1.535","article-title":"Mouse CD1-specific NK T cells: Development, specificity, and function","volume":"15","author":"Bendelac","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.176.1.269","article-title":"Murine thymic CD4+ T cell subsets: A subset (Thy0) that secretes diverse cytokines and overexpresses the V beta 8 T cell receptor gene family","volume":"176","author":"Hayakawa","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/ni.2051","article-title":"A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties","volume":"12","author":"Uldrich","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/372691a0","article-title":"Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells","volume":"372","author":"Beckman","year":"1994","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1034\/j.1399-0039.2002.600501.x","article-title":"The CD1 family and T cell recognition of lipid antigens","volume":"60","author":"Dutronc","year":"2002","journal-title":"Tissue Antigens"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.182.6.1913","article-title":"TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1","volume":"182","author":"Brutkiewicz","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.7542404","article-title":"CD1-restricted T cell recognition of microbial lipoglycan antigens","volume":"269","author":"Sieling","year":"1995","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","volume":"1","author":"Terabe","year":"2000","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ni0805-754","article-title":"CD1d antigen presentation: Treats for NKT cells","volume":"6","author":"Godfrey","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2567.2000.00952.x","article-title":"Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells","volume":"99","author":"Nicol","year":"2000","journal-title":"Immunology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of NKT cell biology: Progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI200423594","article-title":"Going both ways: Immune regulation via CD1d-dependent NKT cells","volume":"114","author":"Godfrey","year":"2004","journal-title":"J. Clin. Invest."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08830180601070195","article-title":"Invariant NKT cells and tolerance","volume":"26","author":"Nowak","year":"2007","journal-title":"Int. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/jm00012a018","article-title":"Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice","volume":"38","author":"Morita","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_16","first-page":"293","article-title":"CD1-restricted T cells and tumor immunity","volume":"314","author":"Swann","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature03408","article-title":"Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections","volume":"434","author":"Mattner","year":"2005","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ni1380","article-title":"Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria","volume":"7","author":"Kinjo","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nature03407","article-title":"Recognition of bacterial glycosphingolipids by natural killer T cells","volume":"434","author":"Kinjo","year":"2005","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.4049\/jimmunol.177.7.4577","article-title":"Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d","volume":"177","author":"Zajonc","year":"2006","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/eji.200526157","article-title":"Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells","volume":"35","author":"Sriram","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1126\/science.1103440","article-title":"Lysosomal glycosphingolipid recognition by NKT cells","volume":"306","author":"Zhou","year":"2004","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1073\/pnas.0611139104","article-title":"Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency","volume":"104","author":"Porubsky","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1615\/CritRevImmunol.v25.i3.20","article-title":"iNKT-cell responses to glycolipids","volume":"25","author":"Parekh","year":"2005","journal-title":"Crit. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1084\/jem.20051625","article-title":"Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity","volume":"202","author":"Zajonc","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cyto.2010.04.016","article-title":"Cytokine dependent and independent iNKT cell activation","volume":"51","author":"Reilly","year":"2010","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.4049\/jimmunol.163.11.5871","article-title":"A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement","volume":"163","author":"Hameg","year":"1999","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1073\/pnas.0604812103","article-title":"Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice","volume":"103","author":"Fujii","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1084\/jem.20031192","article-title":"Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide","volume":"198","author":"Schmieg","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1038\/emboj.2011.145","article-title":"Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis","volume":"30","author":"Aspeslagh","year":"2011","journal-title":"EMBO J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tips.2005.03.005","article-title":"Immunotherapeutic potential for ceramide-based activators of iNKT cells","volume":"26","author":"Berkers","year":"2005","journal-title":"Trends. Pharmacol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.4049\/jimmunol.165.5.2665","article-title":"The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent","volume":"165","author":"Smyth","year":"2000","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/1097-0215(20010215)91:4<523::AID-IJC1087>3.0.CO;2-L","article-title":"Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells","volume":"91","author":"Shin","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.278.5343.1623","article-title":"Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors","volume":"278","author":"Cui","year":"1997","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2567.1999.00726.x","article-title":"Expression of CD1D mRNA transcripts in human choriocarcinoma cell lines and placentally derived trophoblast cells","volume":"96","author":"Jenkinson","year":"1999","journal-title":"Immunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1432-1033.2004.04387.x","article-title":"Altered expression of CD1d molecules and lipid accumulation in the human hepatoma cell line HepG2 after iron loading","volume":"272","author":"Cabrita","year":"2005","journal-title":"FEBS J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e11311","DOI":"10.1371\/journal.pone.0011311","article-title":"Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide","volume":"5","author":"Nowak","year":"2010","journal-title":"PLoS One"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.1073\/pnas.122636199","article-title":"Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells","volume":"99","author":"Sriram","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"ref_41","first-page":"3058","article-title":"Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells","volume":"63","author":"Stewart","year":"2003","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2011.04.017","article-title":"Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects","volume":"140","author":"Exley","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","article-title":"Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load","volume":"116","author":"Molling","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Tahir","year":"2001","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e8646","DOI":"10.1371\/journal.pone.0008646","article-title":"iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells","volume":"5","author":"Bellone","year":"2010","journal-title":"PLoS One"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sj.pcan.4500296","article-title":"Pathologic progression of autochthonous prostate cancer in the TRAMP model","volume":"2","author":"Gingrich","year":"1999","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_47","first-page":"3325","article-title":"Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model","volume":"57","author":"Foster","year":"1997","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2008-04-149831","article-title":"Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer","volume":"112","author":"Chang","year":"2008","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_50","first-page":"3702","article-title":"A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors","volume":"8","author":"Giaccone","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.4049\/jimmunol.171.8.4020","article-title":"Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells","volume":"171","author":"Crowe","year":"2003","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-007-0373-5","article-title":"Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer","volume":"57","author":"Uchida","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3768::AID-IMMU3768>3.0.CO;2-G","article-title":"NKT cells are phenotypically and functionally diverse","volume":"29","author":"Hammond","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ni827","article-title":"Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs","volume":"3","author":"Fujii","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","article-title":"Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma","volume":"100","author":"Kunii","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: What's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1084\/jem.182.4.993","article-title":"CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice","volume":"182","author":"Cardell","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U","article-title":"Self glycolipids as T-cell autoantigens","volume":"29","author":"Shamshiev","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00262-008-0495-4","article-title":"A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity","volume":"57","author":"Berzofsky","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20022227","article-title":"Transforming growth factor-beta production and myeloid cells are an effector mechanism through which \u201cCD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence","volume":"198","author":"Terabe","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.4049\/jimmunol.179.8.5126","article-title":"Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis","volume":"179","author":"Ambrosino","year":"2007","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1158\/0008-5472.CAN-05-3421","article-title":"CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta","volume":"66","author":"Terabe","year":"2006","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1182\/blood-2007-05-092866","article-title":"Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma","volume":"111","author":"Renukaradhya","year":"2008","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","article-title":"Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC)","volume":"137","author":"Hontscha","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Negrin","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1015415928521","article-title":"Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice","volume":"22","author":"Verneris","year":"2002","journal-title":"J. Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Laport, G.G., Sheehan, K., Baker, J., Wong, R.M., Lowsky, R., Johnston, L.J., Shizuru, J.A., Miklos, D., Arai, S., Benjamin, J.E., Weng, W.K., and Negrin, R.S. (2011). Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant.","DOI":"10.1016\/j.bbmt.2011.05.012"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.169.3.1444","article-title":"Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8 + T cells","volume":"169","author":"McMahon","year":"2002","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1128\/JVI.74.15.7032-7038.2000","article-title":"The virus-specific and allospecific cytotoxic T-lymphocyte response to lymphocytic choriomeningitis virus is modified in a subpopulation of CD8(+) T cells coexpressing the inhibitory major histocompatibility complex class I receptor Ly49G2","volume":"74","author":"Peacock","year":"2000","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","article-title":"Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell","volume":"126","author":"Linn","year":"2009","journal-title":"Immunology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00002371-200111000-00007","article-title":"Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations","volume":"24","author":"Marten","year":"2001","journal-title":"J. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.urolonc.2007.09.003","article-title":"Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells","volume":"27","author":"Wang","year":"2009","journal-title":"Urol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/07357900701511789","article-title":"Enhanced antitumor effects by the coculture of allotumor RNA-pulsed dendritic cells with autologous cytokine-induced killer cells on hormone-refractory prostate cancer","volume":"25","author":"Pang","year":"2007","journal-title":"Cancer Invest."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Finke","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/1078-0432.CCR-06-0114","article-title":"A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer","volume":"12","author":"Motohashi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_81","first-page":"3997","article-title":"Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer","volume":"28","author":"Wu","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/14653240903121252","article-title":"Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery","volume":"11","author":"Li","year":"2009","journal-title":"Cytotherapy"},{"key":"ref_83","first-page":"465","article-title":"Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma","volume":"25","author":"Su","year":"2010","journal-title":"Cancer Biother. Radiopharm"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:57:26Z","timestamp":1760219846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,20]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,9]]}},"alternative-id":["cancers3033661"],"URL":"https:\/\/doi.org\/10.3390\/cancers3033661","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,20]]}}}